Figure 3.

Achievement and maintenance of non-detectable viral-load values in patients enrolled in dolutegravir-based two-drug regimens clinical trials. Histograms represent individual studies—not a head-to-head comparison. (a) Proportion of drug-naïve participants with TND values by week of treatment from GEMINI-1 and -2 studies (snapshot analysis). (b) Proportion of treatment-experienced participants with TND values by week of treatment from the TANGO study (snapshot analysis). (c) Proportion of TND values by week of treatment for treatment-experienced participants with TND at baseline, from the SWORD-1 and SWORD-2 studies. 3TC = lamivudine; cART = combination antiretroviral therapy; DTG = dolutegravir; FTC = emtricitabine; RPV = rilpivirine; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TND = Target not detected.